share_log

Needham Reiterates Buy on Cytokinetics, Maintains $108 Price Target

Moomoo 24/7 ·  Apr 9 05:54

Needham analyst Serge Belanger reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $108 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment